Sales & Marketing News | pharmaphorum

News

Changes at the top of Sarepta, Alkermes, as CEOs depart

Two long-serving pharma CEOs have announced their departures, as Sarepta's Doug Ingram and Alkermes' Richard Pops announce their retirement.

News

Black background scattered with red 'SALE' tickets

Novo Nordisk to cut GLP-1 prices in tough US market

Novo Nordisk has turned to pricing as a means to shore up its position in the increasingly competitive market for GLP-1 agonist therapies in the US.

News

MSD splits pharma business, hiving off oncology

MSD is separating its cancer and non-cancer pharma operations as it prepares for the looming loss of patent protection for $31bn blockbuster Keytruda.

News

FDA clears first all-oral combo for first-line CLL treatment

AstraZeneca's Calquence and AbbVie/Roche's Venclexta have become the first all-oral, fixed-duration regimen for newly-diagnosed CLL.

News

What next for pharma as SCOTUS strikes down Trump tariffs?

The centrepiece of President Trump's economic strategy has been shattered after the Supreme Court ruled his sweeping tariffs are illegal.

News

FDA starts review of Regeneron's drug for rare disease FOP

Can Regeneron's drug for ultra-rare bone disease FOP pick up the baton from Ipsen's Sohonos, whose growth has stalled?

Changes at the top of Sarepta, Alkermes, as CEOs depart

Novo Nordisk to cut GLP-1 prices in tough US market

MSD splits pharma business, hiving off oncology

FDA clears first all-oral combo for first-line CLL treatment

What next for pharma as SCOTUS strikes down Trump tariffs?

FDA starts review of Regeneron's drug for rare disease FOP

Judge backs Lilly in Novo lawsuit over weight-loss drug ads

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks